ERBB2 and breast carcinoma: Approximately one quarter of these women will be diagnosed with breast cancer that is human epidermal growth factor receptor 2 positive (HER2 +) [3], with overexpression of HER2 associated with tumour cell proliferation, lower treatment efficacy, higher rates of metastases and poorer clinical outcomes [3–5].